Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.62 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.62 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5154490 | 1.00 | PDE4B (0.62) | PDE4BNR3C1PGRPDE4D | |
| SCHEMBL4940848 | 0.96 | PDE4B (0.63) | PDE4BNR3C1PGRPDE4D | |
| SCHEMBL4938225 | 0.89 | PDE4B (0.54) | PDE4BNR3C1PGRPDE4D | |
| SCHEMBL4941218 | 0.89 | PDE4B (0.57) | PDE4BNR3C1PGRPDE4D | |
| SCHEMBL4939623 | 0.88 | PDE4B (0.64) | PDE4BNR3C1PGRPDE4D | |
| SCHEMBL4936746 | 0.88 | PDE4B (0.64) | PDE4BNR3C1PGRPDE4D | |
| SCHEMBL4934361 | 0.88 | PDE4B (0.64) | PDE4BNR3C1PGRPDE4D | |
| SCHEMBL5173840 | 0.87 | PDE4B (0.58) | PDE4BNR3C1PDE4D | |
| SCHEMBL4938151 | 0.87 | PDE4B (0.58) | PDE4BNR3C1PDE4D | |
| SCHEMBL4938493 | 0.86 | PDE4B (0.57) | PDE4BNR3C1PGRPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | claimed |
| EP-1740590-A1 | PYRAZOLO [3,4- b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-01-10 | — | — | EP | claimed |
| WO-2005090354-A1 | PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | PDE4B, PDE3B, PDE4A | PDE4B 1/4885NR3C1 964/4885PGR 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.